Two specific variations in the genetic sequence of the glucocorticoid receptor — which determines how well glucocorticoid regulates metabolism and other key processes — were seen to markedly increase a person’s risk of systemic lupus erythematosus (SLE), a study conducted in China reports. Published in the International Journal of…
Patients who have their lupus treated at more than one care facility are at higher risk of developing severe infections and other diseases, a study indicates. The researchers called the tendency to go to more than one institution “fragmentation of treatment.” Their study, “Disease Outcomes and Care…
Lupus patients with certain antibodies are more prone to getting blood clots, but researchers might have come up with a way of preventing such clots from forming in the first place. In a new mouse study, researchers at the University of Michigan Medical School found that targeting the PSGL-1 molecule…
Good gut bacteria from yogurt may be able to reduce kidney inflammation in systemic lupus erythematosus patients — if results of a mouse study can be translated to humans, that is. Mice with lupus who ate lactobacillus bacteria had stronger anti-inflammatory immune reactions and less kidney disease than control mice, according…
Nimbus Therapeutics, which uses computer analysis to identify and develop therapies for autoimmune diseases like lupus, has established a long-term strategic alliance with Celgene, a company that focuses on immunology. The agreement promises to foster the development of new therapies for diseases triggered by imbalanced immune system responses. Nimbus…
Cognitive impairment is highly prevalent in patients with systemic lupus erythematosus (SLE), a study from Canada finds. The research also addressed the validity of different screening tools for this difficulty in lupus, and found the Montreal Cognitive Assessment (MoCA) may be more suitable that others. The study, “…
Patients with systemic lupus erythematosus (SLE) report high levels of satisfaction when Benlysta (belimumab) therapy was self-administered using an autoinjector, a small study reports. The study, “Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus,” was published in…
The presence of anti-SS-B autoantibodies alone was not associated with connective tissue disease (CTD) in daily clinical practice, particularly in the case of primary Sjogren’s syndrome but also lupus patients, a new study shows. The study, “Isolated positive anti-SS-B autoantibodies are not related to clinical features of…
New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed…
Japan’s Ministry of Health, Labor and Welfare has approved Benlysta (belimumab) as an add-on therapy to treat adult patients with systemic lupus erythematosus (SLE) who cannot receive or don’t respond to existing therapies. The drug, developed by GlaxoSmithKline (GSK), will be available in two formulations, given via intravenous (IV) or subcutaneous (SC)…